Essential thrombocytosis (ET) is a hematopoietic stem cell disorder characterized uniquely by the overproduction of platelets in the absence of a definable stimulus. Approximately 50% of ET patients express a mutation of the Janus-associated kinase 2 gene (JAK2 V617F). 1 These patients also appeared to have a 'polycythemia vera (PV)-like' phenotype compared to their JAK2 V617F-negative counterparts. 2 However, quantitative analysis of the neutrophil JAK2 V617F allelic burden indicated that ET patients generally have a lower neutrophil JAK2 V617F allele percentage than JAK2 V617F-positive PV or idiopathic myelofibrosis (IMF) patients. 3, 4 We, therefore, studied 80 consecutive ET patients to determine whether the quantitative neutrophil JAK2 V617F allele burden in ET is correlated with gender, disease presentation, disease evolution or vascular complications. Patients were prospectively enrolled between 2005 and 2006; blood samples were obtained at the time of clinical assessment, and quantitative JAK2 V617F allele percentages were measured from neutrophil genomic DNA or platelet cDNA, as described previously. 3 Median disease duration at the time of phenotypic and genotypic analysis for the entire cohort was 6 years (range 0.5-26 years). Similar to studies with equivalent JAK2 V617F assay sensitivity, 1,5 47% of our patients were JAK2 V617F-positive. Also in keeping with other observations, JAK2 V617F-positive patients were significantly older at diagnosis than JAK2 V617F-negative patients (59 versus 38 years, Pp0.001).
1 Median disease duration of the JAK2 V617F-positive ET patients was also significantly shorter than the JAK2 V617F-negative patients (3 versus 8 years, respectively; P ¼ 0.022), although the ranges were similar (Table 1a) . JAK2 V617F mutation status also did not correlate with hydroxyurea, anagrelide or interferon-a use (Table 1) . While the median hemoglobin concentration was higher in the JAK2 V617-positive group, this did not reach statistical significance when controlled for gender. Similarly, there was no significant difference in the white cell count or platelet count between JAK2 V617-positive and negative patients, nor was there any correlation with a family history of a myelo-proliferative disorder (MPD), which was present in nine JAK2 V617F-positive patients (two male, seven female) and six JAK2 V617F-negative patients (three male, three female).
In the 37 JAK2 V617F-positive ET patients in the present study, the median neutrophil allele percentage was 43% (range 11-64%). The JAK2 V617F allele percentage was not a function of disease duration, since patients early on or decades into their disease had varied allele percentages ( Figure 1a ). However, when stratified by gender, we found that women had significantly lower neutrophil JAK2 V617F allele percentages compared to men, regardless of disease duration (36 versus 46%, P ¼ 0.016). We also measured the JAK2 V617F allele burden simultaneously in neutrophil genomic DNA and platelet cDNA from the same blood sample in 27 patients and found that the median neutrophil JAK2 V617F allele percentage (16.0%) was lower than the median platelet allele percentage (38.5%) (Po0.001). When Table 1a Epidemiological and clinical data in 80 ET patients Letters to the Editor stratified by gender, however, the differences between platelet and neutrophil allele burdens retained significance in women only (Figure 1b) , in four of whom JAK2 V617F was detected only in platelets (Figure 1b) . These four women were otherwise phenotypically similar to the other women in the cohort. Similar to these findings, monoclonal hematopoiesis restricted to platelets in women with ET has been reported previously, 6 and more recently, JAK2 V617F expression was also observed only in platelets in a small fraction of ET patients. 7 Migraine, erythromelalgia and transient ischemic attacks occurred in 25, 14 and 9% of our patients, respectively, during the course of their disease, while acute coronary syndrome, stroke and peripheral arterial thrombosis occurred in 7, 5 and 4% of the patients, respectively. Neither JAK2 V617F mutational status nor allele burden correlated with these events including those in whom JAK2 V617F was expressed solely in platelets (Table 1b) . Hemorrhage occurred in only two patients, both of whom were JAK2 V617F-negative women. During the study period, three patients transformed to PV and three to IMF (Figure 1b) . Median disease duration at time of conversion was 10 years (range, 8-26 years). Four of the six patients were JAK2 V6127F-positive, with a median JAK2 V617F allele burden of Figure 1 (a) Neutrophil JAK2 V617F allele percentages in ET. Eighty ET patients were stratified by neutrophil JAK2 V617F allele percentage and disease duration at the time of genomic analysis. The median neutrophil JAK2 V617F allele percentage of 43% is indicated by the dotted line. The patients who developed phenotypic change to PV and IMF are indicated by the black arrows and white arrows, respectively. (b) JAK2 V617F percentages in neutrophils and platelets. Neutrophil genomic DNA and platelet cDNA were isolated simultaneously from blood samples in 27 ET patients; JAK2 V617F was detected in the platelets of 18 of the subjects and is presented here. Median neutrophil JAK2 V617F allele percentage was greater in males (37%) than in females (18.5%) (P ¼ 0.05) while the median platelet JAK2 V617F allele percentage (44.5%) was greater than in neutrophils (Po0.001) in females. Paired values of four women in which JAK2 V617F was detected only in platelets are indicated by the gray lines. In nine subjects, JAK2 V617F was not detected in either platelets or neutrophils (data not shown). ET, essential thrombocytosis; IMF, idiopathic myelofibrosis; JAK, Janus-associated kinase; PV, polycythemia vera. Abbreviations: ET, essential thrombocytosis; JAK, Janus-associated kinase.
Letters to the Editor 60% (range 45-64%), which was significantly higher than the allele burden of the entire JAK2 V617F-positive cohort (P ¼ 0.01). These data indicate significant heterogeneity in JAK2 V617F allele burden in ET with respect to cell type, age and gender but lack of correlation with disease duration and micro-or macrovascular thrombosis. The lack of correlation of JAK2 V617F allele burden with vascular events in our ET cohort is similar to the previous negative experience relating JAK2 V617F expression to vascular risk in ET, 5, 8 but contrasts with some other observations. 2 These differences may reflect the inadequacy of clinical criteria to distinguish ET from PV, reliance in other studies solely on qualitative JAK2 V617F expression as a marker for ET, and possibly ascertainment bias of the recruited ET patients.
Finally, the gender differences in both the neutrophil allele burden and the discrepancy between neutrophil and platelet burden in ET suggest the existence of important but as yet unidentified biological modifiers of JAK2 V617F expression. Many subjects expressing JAK2 V617F harbor this mutation at low levels that do not appear to become clonally dominant in the peripheral blood, and our data indicate that women may suppress the tendency for clonal expansion in the peripheral blood more effectively than men. Importantly, quantitative differences in the neutrophil JAK2 V617F allelic burden between ET and PV suggest biological differences between these disorders, but expression of the mutation per se does not appear to account for a predisposition to either thrombosis or hemorrhage in ET patients.
